دورية أكاديمية
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic
العنوان: | Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
---|---|
المؤلفون: | Papadimitriou-Olivgeris, Matthaios, Kolonitsiou, Fevronia, Kefala, Sotiria, Spiliopoulou, Anastasia, Aretha, Diamanto, Bartzavali, Christina, Siapika, Argyro, Marangos, Markos, Fligou, Fotini |
المصدر: | Brazilian Journal of Infectious Diseases. January 2022 26(2) |
بيانات النشر: | Brazilian Society of Infectious Diseases, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | Candidemia, COVID-19, SARS-CoV-2, Critically-ill patients, ICU, Corticosteroids |
الوصف: | Background Patients with severe Coronavirus Disease 2019 (COVID-19) are treated with corticosteroids. Aim We aimed to evaluate the role of corticosteroid treatment in candidemia development during the COVID-19 pandemic. Methods This retrospective study was conducted in a Greek ICU, from 2010 to August 2021, encompassing a pre-pandemic and a pandemic period (pandemic period: April 2020 to August 2021). All adult patients with candidemia were included. Results During the study period, 3,572 patients were admitted to the ICU, 339 patients during the pandemic period, of whom 196 were SARS-CoV-2-positive. In total, 281 candidemia episodes were observed in 239 patients, 114 in the pandemic period. The majority of candidemias in both periods were catheter-related (161; 50.4%). The incidence of candidemia in the pre-pandemic period was 5.2 episodes per 100 admissions, while in the pandemic period was 33.6 (p < 0.001). In the pandemic period, the incidence among COVID-19 patients was 38.8 episodes per 100 admissions, while in patients without COVID-19 incidence was 26.6 (p= 0.019). Corticosteroid administration in both periods was not associated with increased candidemia incidence. Conclusions A significant increase of candidemia incidence was observed during the pandemic period in patients with and without COVID-19. This increase cannot be solely attributed to immunosuppression (corticosteroids, tocilizumab) of severe COVID-19 patients, but also to increased workload of medical and nursing staff. |
نوع الوثيقة: | article |
وصف الملف: | text/html |
اللغة: | English |
تدمد: | 1413-8670 |
DOI: | 10.1016/j.bjid.2022.102353 |
URL الوصول: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702022000200502 |
حقوق: | info:eu-repo/semantics/openAccess |
رقم الأكسشن: | edssci.S1413.86702022000200502 |
قاعدة البيانات: | SciELO |
كن أول من يترك تعليقا!